Dianthus Therapeutics (DNTH) Share-based Compensation (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Share-based Compensation of $5.8 million for Q3 2025, up 50.89% year-over-year from $3.8 million in Q3 2024, and up 1.54% quarter-over-quarter from $5.7 million in Q2 2025.
Dianthus Therapeutics (DNTH) Share-based Compensation (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $5.8 million for Q3 2025.
- In Q3 2025, Share-based Compensation rose 50.89% year-over-year to $5.8 million; the TTM figure through Sep 2025 stood at $20.7 million (up 113.7% YoY), while the FY2024 annual figure was $41.5 million, up 425.32% from the prior year.
- Share-based Compensation for Q3 2025 stood at $5.8 million, up from $5.7 million in the prior quarter.
- The five-year high for Share-based Compensation was $5.8 million in Q3 2025, with the low at $462000.0 in Q2 2023.
- The 5-year median for Share-based Compensation is $2.1 million (2021), against an average of $2.5 million.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation sank 82.6% in 2022, then jumped 571.21% in 2024.
- Dianthus Therapeutics' Share-based Compensation stood at $2.2 million in 2021, then tumbled by 76.5% to $513000.0 in 2022, then surged by 41.52% to $726000.0 in 2023, then jumped by 439.67% to $3.9 million in 2024, then soared by 47.88% to $5.8 million in 2025.
- Business Quant data shows DNTH's Share-based Compensation at $5.8 million in Q3 2025, $5.7 million in Q2 2025, and $5.3 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.79 Mn |
| Sep 30, 2025 | 5.79 Mn |
| Jun 30, 2025 | 5.71 Mn |
| Jun 30, 2025 | 5.71 Mn |
| Mar 31, 2025 | 5.32 Mn |
| Mar 31, 2025 | 5.32 Mn |
| Dec 31, 2024 | 3.92 Mn |
| Dec 31, 2024 | 3.92 Mn |
| Sep 30, 2024 | 3.84 Mn |
| Sep 30, 2024 | 3.84 Mn |
| Jun 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 3.10 Mn |
| Mar 31, 2024 | 2.04 Mn |
| Mar 31, 2024 | 2.04 Mn |
| Dec 31, 2023 | 726,000.00 |
| Dec 31, 2023 | 726,000.00 |
| Sep 30, 2023 | 1.18 Mn |
| Sep 30, 2023 | 1.18 Mn |
| Jun 30, 2023 | 462,000.00 |
| Jun 30, 2023 | 462,000.00 |